MKI67 and breast carcinoma: There are currently immunohistochemical markers that allow breast cancer to be stratified into clinically meaningful subgroups on the basis of pathological factors, including tumor size, histological grade, lymph node involvement, and clinically relevant predictive biomarkers, such as ER, PR, HER2 and Ki-67 expression [2].